MedTrace Logo

SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection

NCT00323544 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2008-07-04

No results posted yet for this study

Summary

This study will investigate whether the simplified regimen of a once daily fixed dose combination of Truvada (emtricitabine and tenofovir disoproxil fumarate \[DF\]) will be associated with a reduced rate of adverse events, seen with long term use of antiretrovirals, as well as improved adherence compared to a twice daily fixed dose combination of Combivir.

Conditions

  • HIV Infections

Interventions

DRUG

zidovudine and lamivudine (Combivir®)

DRUG

emtricitabine and tenofovir DF

Sponsors & Collaborators

Principal Investigators

  • Claudio Avila, MD · Gilead Sciences, Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2007-06-30
Completion
2007-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00323544 on ClinicalTrials.gov